The 2004 WHO classification of bladder tumors: A summary and commentary;Clasificación de la OMS 2004 para los tumores vesicales: Resumen y comentarios

Actas Urologicas Espanolas

Volumn 31, Issue 9, 2007, Pages 978-988

  Álvarez, Kindelán J ^a   Campos, Hernández J P ^a   López, Beltrán A ^b   Requena, Tapia M J ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b Universidad de Cordoba   (Spain)

Author keywords

Bladder cancer; Genetics; Pathology

Indexed keywords

BLADDER TUMOR; CLASSIFICATION; HUMAN; PATHOLOGY; REVIEW; UROTHELIUM; WORLD HEALTH ORGANIZATION;

HUMANS; URINARY BLADDER NEOPLASMS; UROTHELIUM; WORLD HEALTH ORGANIZATION;

EID: 41649101671     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0210-4806(07)73761-0     Document Type: Article

References (38)

1. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66(6 Suppl 1):4-34.
2. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998;22(12): 1435-1448.
3. Montironi R, López-Beltran A, Mazzucchelli R, Bostwick DG. Classification and grading of the non-invasive urothelial neoplasms: Recent advances and controversies: J Clin Pathol. 2003;56(2):91-95.
4. Montironi R, Scarpelli M, Mazzucchelli R, Hamilton PW, Thompson D, Ranger-Moore J, et al. Subvisual changes in chromatin organization state are detected by karyometry in the histologically normal urothelium in patients with synchronous papillary carcinoma. Hum Pathol. 2003;34(9):893-901.
5. Sauter G, Algaba F, Amin MR, Busch C, Cheville J, Gasser T, et al. Noninvasive urothelial neoplasias;WHO classification of noninvasive papillary urothelial tumors. En World Health Organization classification of tumors. Pathology and genetics of tumors of the urinary system and male genital organs. Eble JN, Epstein JI, Sesterhenn I (eds): Lyon, IARCC 2004
6. Lopez-Beltran A, Luque RJ, Moreno A, Bollito E, Carmona E, Montironi R, The pagetoid variant of bladder urothelial carcinoma in situ: A clinicopathological study of 11 cases. Virchows Arch. 2002;441(2):148-153.
7. López-Beltrán A, Cheng L, Andersson L, Brausi M, de Matteis A, Montironi R, et al. Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation. Virchows Arch. 2002;440(1):3-11.
8. Hartmann A, Moser K, Kriegmair M, Hofstetter A, Hofstaedter F, Knuechel R. Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. Am J Pathol. 1999; 154 (3):721-727.
9. Muto S, Horie S, Takahashi S, Tomita K, Kitamura T. Genetic and epigenetic alterations in normal bladder epithelium in patients with metachronous bladder cancer. Cancer Res. 2000;60(15):4021-4025.
10. Harnden P, Eardley I, Joyce AD, Southgate J. Cytokeratin 20 as an objective marker of urothelial dysplasia. Br J Urol. 1996;78(6):870-875.
11. Hartmann A, Schlake G, Zaak D, Hungerhuber E, Hofstetter A, Hofstaedter F et al. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res. 2002;62(3): 809-818.
12. Cheng L, Cheville JC, Neumann RM, Bostwick DG. Natural history of urothelial dysplasia of the bladder. Am J Surg Pathol. 1999;23(4):443-447.
13. McKenney JK, Gomez JA, Desai S, Lee MW, Amin MB. Morphologic expressions of urothelial carcinoma in situ: A detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion. Am J Surg Pathol. 2001;25(3):356-362.
14. Helpap B, Kollermann J. Assessment of basal cell status and proliferative patterns in flat and papillary urothelial lesions: A contribution to the new WHO classification of the urothelial tumors of the urinary bladder. Hum Pathol. 2000;31(6):745-750.
15. Bostwick DG, Ramnani D, Cheng L. Diagnosis and grading of bladder cancer and associated lesions. Urol Clin North Am. 1999;26(3):493-507.
16. Cordon-Cardo C, Cote RJ, Sauter G. Genetic and molecular markers of urothelial premalignancy and malignancy. Scand J Urol Nephtol. 2000;(205):82-93.
17. Simon R, Jones PA, Sidransky D, Cordon-Cardo C, Cairns P, Amin MB et al. Genetics and predictive factors of noninvasive urothelial neoplasias, WHO classification of noninvasive papillary urothelial tumors. En World Health Organization Classification of tumors. Pathology and genetics of tumors of the urinary system and male genital organs. Editores Eble JN, Epstein JLSesterhenn I;Lyon, IARCC 2004;pp 120-123.
18. Stampfer DS, Carpinito GA, Rodriguez-Villanueva J, Willsey LW, Dinney CP, Grossman HB, et al. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol. 1998;159(2):394-398.
19. Mckenney JK, Amin MB, Young RH. Urothelial (transitional cell) papilloma of the urinary bladder: A clinico-pathologic study of 26 cases. Mod Pathol. 2003;16(7): 623-629.
20. Van Rhijn BW, Montironi R, Zwartholl EC, Jobsis AC, van der Kwast TH. Frequent FGFR3 mutations in utothelial papilloma. J Pathol. 2002;198(2):245-251.
21. Sauter G. Inverted papilloma, WHO classification of non-invasive papillary urothelial tumors. En World Health Organization Classification of tumors. Pathology and genetics of tumors of the urinary system and male genital organs. Editado por Eble JN, Epstein JI, Sesterhenn I (eds): Lyon. IARCC 2004: 114.
22. Holmang S, Andius P, Hedelin H, Wester K, Busch C, Johansson SL. Stage progression in Ta papillary urothelial tumors: Relationship to grade, immunohistochemical expression of tumor markers. mitotic frequency and DNA ploidy. J Urol. 2001;165(4):1124-1128.
23. Holmang S, Johansson SL, Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression. J Urol. 2002;167: 1634-1637.
24. Cheng L, Neumann RM, Bostwick DG. Papillary urothelial neoplasms of low malignant potential. Clinical and biologic implications. Cancer. 1999;86(10):2102-2108.
25. Cheng L, MacLennan GT, Zhang S, Wang M, Pan CX, Koch MO. Laser capture microdissection analysis reveals frequent allelic losses in papillary urothelial neoplasm of low malignant potential of the urinary bladder. Cancer. 2004; 101(1):183-188.
26. Fujii Y, Kawakarni S, Koga F, Nemoto T, Kihara K. Long-term outcome of bladder papillary urothelial neoplasms of low malignant potential. BJU Int. 2003;92(6):559-562.
27. Desai S, Lim SD, Jimenez RE, Chun T, Keane TE. McKenney JK, et al. Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia. Mod Pathol. 2000; 13(12):1315-1323.
28. Alsheikh A, Mohamedali Z, Jones E, Masterson J, Gilks CB. Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/Internattional Society of Urologic Pathology. Mod Pathol. 2001;14(4):267-272.
29. Alvarez-Kindelán J, Lopez Beltran A, Anglada Curado F, Moreno Arcas P, Carazo Carazo JL, Regueiro Lopez JC, et al. Diferencias clínico-patológicas entre neoplasia vesical de bajo potencial maligno y carcinoma de bajo grado. Actas Urol Esp. 2001;25(9): 645-650.
30. Samaratunga H, Makarov DV, Epstein JL. Comparison of WHO/ISUP and WHO classification of noninvasive papillary urothelial neoplasms for risk of progression. Urology. 2002;60(2):315-319.
31. Oosterhuis JW, Schapers RF, Janssen-Heijnen ML, Pauwels RP, Newling DW. Histological grading of papillary. urothelial carcinoma of the bladder: Prognostic value of the 1998 WHO/ISUP classification system and comparison with conventional grading system. J Clin Pathol. 2002;55 (12):900-905.
32. Pich A, Chiusa L, Formiconi A, Galliano D, Bortolin P, Navone R. Biologic differences between noninvasive papillary urothelial neoplasms of low malignant potencial and low grade (grade 1) papillary carcinomas of the bladder. Am J Surg Pathol. 2001;25(12):1528-1533.
33. Schmitz-Drager BJ, van Roeyen CR, Grimm MO, Gerharz CD, Decken K, Schulz WA, et al. p53 accumulation in precursor lesions and early stages of bladder cancer. World J Urol. 1994;12(2):79-83.
34. Lopez Beltran A, Bassi P, Pavone Macaluso M, Montironi R. Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. Eur Urol. 2004;45(3):257-266.
35. Richter J, Jiang F, Gorog JP, Sartorius G, Egenter C, Gasser TC, et al. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res. 1997;57 (14):2860-2864.
36. Richter J, Wagner U, Schrami P, Maurer R, Alund G, Knonagel H et al. Chromosomal imbalances are associated with a high risk of progression in early invasive (pT1) urinary bladder cancer. Cancer Res. 1999;59(22): 5687-5691.
37. Bostwick DG, Mikuz G. Urothelial papillary (exophytic) neoplasms. Virchows Arch. 2002;441(2):109-116.
38. Busch C, Algaba F. The WHO/ISUP 1998 and WHO 1999 systems for malignancy grading of bladder cancer. Scientific foundation and translation to one another and previous systems. Virchows Arch. 2002;441(2):105-108.